您的位置: 首页 > 2023年6月 第54卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

乙酰半胱氨酸泡腾片联合布地格福气雾剂治疗慢性阻塞性肺疾病疗效及对患者肺功能的影响

Efficacy of acetylcysteine effervescent tablets combined with budigraf aerosol in the treatment of COPD and its effect on pulmonary function of patients

来源期刊: 广州医药 | 83-87 发布时间:2023-07-27 收稿时间:2025/11/13 18:33:46 阅读量:30
作者:
关键词:
乙酰半胱氨酸泡腾片布地格福气雾剂慢性阻塞性肺疾病
acetylcysteine effervescent tabletbudigraf aerosolchronic obstructive pulmonary disease
DOI:
10.3969/j.issn.1000-8535.2023.06.015
收稿时间:
2022-08-22 
修订日期:
 
接收日期:
 
引用总数:
3  
目的 探讨乙酰半胱氨酸泡腾片联合布地格福气雾剂治疗慢性阻塞性肺疾病疗效及对患者肺功能的影响。方法 以2020年4月—2022月4月在本院诊治的84例慢性阻塞性肺疾病患者作为研究对象,根据1∶1简单分配原则把患者分为联合组与对照组各42例。对照组行传统治疗,联合组在对照组治疗的基础上,再给予乙酰半胱氨酸泡腾片联合布地格福气雾剂治疗,联合组与对照组都治疗观察4周。检测患者的疗效、肺功能与血清超敏C反应蛋白(hs-CRP)与降钙素原(PCT)含量变化情况。结果 联合组治疗后的总有效率与对照组相比有提高(P<0.05)。治疗后,联合组与对照组的第一秒用力呼气容积占用力肺活量百分比(FEV1/FVC)、第一秒用力呼气容积占预计值百分比(FEV1%)更高(P<0.05),且联合组与对照组对比有提高(P<0.05)。联合组治疗后的疾病影响、活动能力、症状部分等SGRQ生活质量评分与对照组相比降低(P<0.05)。联合组与对照组治疗后的血清 hs-CRP与 PCT含量低于治疗前(P<0.05),联合组与对照组相比也降低(P<0.05)。结论 乙酰半胱氨酸泡腾片联合布地格福气雾剂治疗慢性阻塞性肺疾病能有效抑制hs-CRP、PCT的表达,能促进改善患者的肺功能,提高治疗效果与生活质量。
Objective To investigate the efficacy of acetylcysteine effervescent tablets combined with budigraf aerosol in the treatment of chronic obstructive pulmonary disease(COPD)and its effect on the pulmonary function of patients.Methods From April 2020 to April 2022,a total of 84 patients with COPD diagnosed and treated in our hospital were selected as the research objects,and the patients were divided into the combination group and the control group with 42 cases in each group,according to the 1∶1 simple allocation principle.The control group were given traditional treatment,and the combination group were given acetylcysteine effervescent tablets combined with budigraf aerosol additionally.Both the combined group and the control group were observed for 4 weeks.The efficacy of patients,lung function and serum hypersensitive C-reactive protein(hs-CRP)and procalcitonin(PCT)levels were detected.Results The total effective rates after treatment in the combination group were higher than the control group(P<0.05).After treatment,The forced expiratory volume in 1 second/forced vital capacity(FEV1/FVC),FEV1% value of the two groups were higher(P<0.05),and the combination group had greater improvement(P<0.05).The SGRQ quality of life scores,such as disease impact,activity ability,and symptom in the combination group were lower(P<0.05).After treatment,the serum high-sensitivity C-reactive protein(hs-CRP)and procalcitonin(PCT)levels in the two groups were significantly lower(P<0.05),and the combined group decreased more(P<0.05).Conclusions Acetylcysteine effervescent tablets combined with budigraf aerosol in the treatment of COPD can effectively inhibit the expression of hs-CRP,PCT,promote the improvement of lung function,improve the treatment effect and quality of life.
1、 赵文卿. 合理氧疗联合乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期的疗效分析[J].国际医药卫生导报,2018,24(3):357-360. 赵文卿. 合理氧疗联合乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期的疗效分析[J].国际医药卫生导报,2018,24(3):357-360.
2、 周璇,石永传,夏元旦,等.乙酰半胱氨酸胶囊对慢性阻塞性肺疾病合并肺间质纤维化患者CT影像及炎症反应的影响[J].药学服务与研究,2021,21(2):158-160. 周璇,石永传,夏元旦,等.乙酰半胱氨酸胶囊对慢性阻塞性肺疾病合并肺间质纤维化患者CT影像及炎症反应的影响[J].药学服务与研究,2021,21(2):158-160.
3、 ZHENG D,WANG J,LI G,et al.Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema[J].Int Immunopharmacol,2021(98):107913. ZHENG D,WANG J,LI G,et al.Preliminary therapeutic and mechanistic evaluation of S-allylmercapto-N-acetylcysteine in the treatment of pulmonary emphysema[J].Int Immunopharmacol,2021(98):107913.
4、 ZHENG D,WANG J,LI G,et al.S-Allylmercapto-N-acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy[J].Biochem Biophys Res Commun,2021(562):83-88. ZHENG D,WANG J,LI G,et al.S-Allylmercapto-N-acetylcysteine ameliorates elastase-induced chronic obstructive pulmonary disease in mice via regulating autophagy[J].Biochem Biophys Res Commun,2021(562):83-88.
5、 葛家艳,尚靖智,任小花.寒喘祖帕颗粒配合乙酰半胱氨酸对COPD患者肺功能、TGF-β及MMP-9水平的影响[J].西部中医药,2021,34(4):113-116. 葛家艳,尚靖智,任小花.寒喘祖帕颗粒配合乙酰半胱氨酸对COPD患者肺功能、TGF-β及MMP-9水平的影响[J].西部中医药,2021,34(4):113-116.
6、 胡小燕,郑晓,嵇华夏,等.N-乙酰半胱氨酸联合理疗对慢性阻塞性肺疾病患者白细胞介素-6和呼吸功能的影响[J].中国药物与临床,2021,21(5):721-724. 胡小燕,郑晓,嵇华夏,等.N-乙酰半胱氨酸联合理疗对慢性阻塞性肺疾病患者白细胞介素-6和呼吸功能的影响[J].中国药物与临床,2021,21(5):721-724.
7、 JIANG C,ZOU J,LV Q,et al.Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].Ann Palliat Med,2021,10(6):6564-6576. JIANG C,ZOU J,LV Q,et al.Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].Ann Palliat Med,2021,10(6):6564-6576.
8、 谢文英,尚立芝,胡文豪,等.慢性阻塞性肺疾病的发病机制及中医药治疗进展[J].中国实验方剂学杂志,2015,21(9):227-230. 谢文英,尚立芝,胡文豪,等.慢性阻塞性肺疾病的发病机制及中医药治疗进展[J].中国实验方剂学杂志,2015,21(9):227-230.
9、 李鹏飞,张建华,李浩闯,等.N-乙酰半胱氨酸对气道NO的影响及其在慢阻肺患者中的应用[J].临床肺科杂志,2022,27(3):472-475,482. 李鹏飞,张建华,李浩闯,等.N-乙酰半胱氨酸对气道NO的影响及其在慢阻肺患者中的应用[J].临床肺科杂志,2022,27(3):472-475,482.
10、 张媛媛,宫硕康,张新,等.呼吸康复治疗联合乙酰半胱氨酸治疗COPD急性加重期的临床观察[J].川北医学院学报,2022,37(1):63-66. 张媛媛,宫硕康,张新,等.呼吸康复治疗联合乙酰半胱氨酸治疗COPD急性加重期的临床观察[J].川北医学院学报,2022,37(1):63-66.
11、 颜廷勇,邵星星,胡晓标.不同剂量阿奇霉素联合N-乙酰半胱氨酸在稳定期COPD患者中的临床疗效对比[J].徐州医科大学学报,2022,42(1):13-16. 颜廷勇,邵星星,胡晓标.不同剂量阿奇霉素联合N-乙酰半胱氨酸在稳定期COPD患者中的临床疗效对比[J].徐州医科大学学报,2022,42(1):13-16.
12、 ZHU X,ZHAN Y,GU Y,et al.Cigarette smoke promotes interleukin-8 production in alveolar macrophages through the reactive oxygen species/stromal interaction molecule 1/Ca(2+)axis[J].Front Physiol,2021(12):733650. ZHU X,ZHAN Y,GU Y,et al.Cigarette smoke promotes interleukin-8 production in alveolar macrophages through the reactive oxygen species/stromal interaction molecule 1/Ca(2+)axis[J].Front Physiol,2021(12):733650.
13、 ZHU L,XU F,KANG X,et al.The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis[J].Mol Med,2021,27(1):97. ZHU L,XU F,KANG X,et al.The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis[J].Mol Med,2021,27(1):97.
14、 李鹏飞,刘利凯,张建华,等.N-乙酰半胱氨酸抗炎作用在慢性阻塞性肺疾病治疗中的研究及进展[J].临床肺科杂志,2022,27(2):285-289. 李鹏飞,刘利凯,张建华,等.N-乙酰半胱氨酸抗炎作用在慢性阻塞性肺疾病治疗中的研究及进展[J].临床肺科杂志,2022,27(2):285-289.
15、 李萍,林桦,张爱丽,等.血清磷水平与老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者机械通气撤机结局的相关性分析[J].中华老年医学杂志,2020,39(6):613-617. 李萍,林桦,张爱丽,等.血清磷水平与老年慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭患者机械通气撤机结局的相关性分析[J].中华老年医学杂志,2020,39(6):613-617.
16、 俞昌赫,甘甜,宋红磊.N-乙酰半胱氨酸联合硫酸特布他林片辅助常规治疗老年COPD并呼吸衰竭对功能康复及β2-MG、CHE血清水平的影响[J].中国老年学杂志,2022,42(6):1385-1389. 俞昌赫,甘甜,宋红磊.N-乙酰半胱氨酸联合硫酸特布他林片辅助常规治疗老年COPD并呼吸衰竭对功能康复及β2-MG、CHE血清水平的影响[J].中国老年学杂志,2022,42(6):1385-1389.
1、辛亚男,吕欣,梁芳,等.乙酰半胱氨酸联合布地奈德雾化对AECOPD患者肺功能及气道炎症反应的影响[J].国际医药卫生导报,2023,29(24):3556-3561. 辛亚男,吕欣,梁芳,等.乙酰半胱氨酸联合布地奈德雾化对AECOPD患者肺功能及气道炎症反应的影响[J].国际医药卫生导报,2023,29(24):3556-3561.
2、汪才平.布地格福吸入气雾剂联合茶碱缓释片治疗COPD稳定期的效果及安全性[J].临床合理用药,2025,18(08):54-57.DOI:10.15887/j.cnki.13-1389/r.2025.08.015. 汪才平.布地格福吸入气雾剂联合茶碱缓释片治疗COPD稳定期的效果及安全性[J].临床合理用药,2025,18(08):54-57.DOI:10.15887/j.cnki.13-1389/r.2025.08.015.
3、左华.乙酰半胱氨酸联合布地奈德治疗慢性阻塞性肺疾病急性加重期患者的效果[J].中国医药指南,2025,23(17):70-72.DOI:10.15912/j.issn.1671-8194.2025.17.021. 左华.乙酰半胱氨酸联合布地奈德治疗慢性阻塞性肺疾病急性加重期患者的效果[J].中国医药指南,2025,23(17):70-72.DOI:10.15912/j.issn.1671-8194.2025.17.021.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录